Reemergence of PML in Natalizumab-Treated Patients - New Cases, Same Concerns

被引：69
作者：
Major, Eugene O. [1 ]
机构：
[1] NINDS, Lab Mol Med & Neurosci, Bethesda, MD 20892 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2009年 / 361卷 / 11期
关键词：
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ANTIBODY NATALIZUMAB; CELLS;
D O I：
10.1056/NEJMp0906248
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1041 / 1043
页数：3
相关论文
共 42 条
  • [1] Considerations for characterizing the risk of PML in natalizumab-treated patients
    Koendgen, Harold
    Ho, Pei-Ran
    Chang, Ih
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 9 : 121 - 121
  • [2] Predicting PML in natalizumab-treated patients: can we do better?
    Derfuss, Tobias
    Kappos, Ludwig
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2013, 84 (11) : 1182 - 1183
  • [3] Review on PML Risk Stratification in Natalizumab-Treated Multiple Sclerosis Patients
    Grigoriadis, Nikolaos C.
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2011, 48 : 61 - 63
  • [4] Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus
    Werner, Milton H.
    Huang, DeRen
    JOURNAL OF NEUROVIROLOGY, 2016, 22 (06) : 871 - 875
  • [5] L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
    Schwab, Nicholas
    Schneider-Hohendorf, Tilman
    Posevitz, Vilmos
    Breuer, Johanna
    Goebel, Kerstin
    Windhagen, Susanne
    Brochet, Bruno
    Vermersch, Patrick
    Lebrun-Frenay, Christine
    Posevitz-Fejfar, Anita
    Capra, Ruggero
    Imberti, Luisa
    Straeten, Vera
    Haas, Juergen
    Wildemann, Brigitte
    Havla, Joachim
    Kuempfel, Tania
    Meinl, Ingrid
    Niessen, Kyle
    Goelz, Susan
    Kleinschnitz, Christoph
    Warnke, Clemens
    Buck, Dorothea
    Gold, Ralf
    Kieseier, Bernd C.
    Meuth, Sven G.
    Foley, John
    Chan, Andrew
    Brassat, David
    Wiendl, Heinz
    NEUROLOGY, 2013, 81 (10) : 865 - 871
  • [6] Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients
    Reid, Carl E.
    Li, Huo
    Sur, Gargi
    Carmillo, Paul
    Bushnell, Steven
    Tizard, Rich
    McAuliffe, Michele
    Tonkin, Christopher
    Simon, Kenneth
    Goelz, Susan
    Cinque, Paola
    Gorelik, Leonid
    Carulli, John P.
    JOURNAL OF INFECTIOUS DISEASES, 2011, 204 (02) : 237 - 244
  • [7] PML in natalizumab-treated multiple sclerosis Modeling errors and risk miscalculations
    Mowry, Ellen M.
    McArthur, Justin C.
    NEUROLOGY, 2017, 88 (12) : 1110 - 1111
  • [8] Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient
    Tortorella, Carla
    Direnzo, Vita
    D'Onghia, Mariangela
    Trojano, Maria
    NEUROLOGY, 2013, 81 (16) : 1470 - 1471
  • [9] Erythroblastaemia in natalizumab-treated patients with multiple sclerosis
    La Gioia, Sara
    Seghezzi, Michela
    Barcella, Valeria
    Dominoni, Paola
    Mecca, Tommaso
    Frigeni, Barbara
    Conti, Marta Zaffira
    Vedovello, Marcella
    Vidali, Matteo
    Rottoli, Mariarosa
    Buoro, Sabrina
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 8 : 141 - 144
  • [10] JC Viremia in Natalizumab-Treated Patients with Multiple Sclerosis
    Major, Eugene O.
    Frohman, Elliot
    Douek, Daniel
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (23) : 2240 - 2241
12345